2Seventy Bio

2seventy Bio, Inc. operates as cell and gene therapy company. It is focused on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

2Seventy Bio reports solid Q2 revenue, navigates competitive challenges

2Seventy Bio's Q2 2023 performance reflects strong revenue driven by ABECMA, with a focus on innovation and patient care. The company faces challenges from competitive dynamics and FDA clinical holds but is strategically positioned to capitalize on opportunities in the oncology space.

2Seventy Bio addresses challenges, highlights ABECMA support at Q3 call

2Seventy Bio navigated a challenging quarter with a focus on ABECMA support and organizational reshaping.
Key presentations at ASH showcased positive outcomes for ABECMA, while concerns around growth and profitability were addressed.
Management's commitment to stakeholders and strategic partnerships position the company for future growth and success.

2Seventy Bio reports robust Q4 earnings, eyes growth opportunities

2Seventy Bio's Q4 2023 earnings call highlighted strong financial performance, cost-saving initiatives, and confidence in Abecma's market potential.
While facing competition challenges and operational considerations, the company remains focused on growth, innovation, and financial sustainability.
Strategic partnerships, upcoming regulatory milestones, and a clear roadmap to breakeven underscore 2Seventy Bio's commitment to long-term success.

2Seventy Bio focuses on Abecma growth post realignment

2Seventy Bio's Q1 2024 performance was solid, with Abecma revenues meeting expectations.
The company's strategic realignment towards Abecma aims for cost efficiency and growth.
Challenges lie in achieving breakeven by 2025 and sustaining Abecma's market position.
Opportunities exist for increased profitability, market expansion, and operational efficiency.

2Seventy Bio focuses on ABECMA, reports strong Q2 earnings

2Seventy Bio's Q2 performance reflects a strategic shift towards profitability and sustainable growth.
The company's strong financial results and cost-saving measures position it well for future success.
While challenges exist, opportunities in product focus and financial management pave the way for a promising future.
Overall, 2Seventy Bio's focus on ABECMA and profitability sets a positive trajectory for the company.

2Seventy Bio reports robust Q3 growth driven by ABECMA success

2Seventy Bio's Q3 2024 performance reflects a strong return to growth, driven by a focus on ABECMA and operational efficiency.
While challenges such as market dynamics and cost optimization persist, the company's strategic strengths and growth opportunities position it well for the future.
With a positive market response to ABECMA and a commitment to expansion, 2Seventy Bio is poised to capitalize on its strengths and navigate challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

2seventy Bio, Inc. operates as cell and gene therapy company. It concentrates on the research, development, and commercialization of transformative treatments for cancer. The company was founded on April 26, 2021 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming 2023 Morgan Stanley Global Healthcare Conference on September 13, 2023 at 3:35pm ET in New York. A live webcast will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. A replay will be archived on 2seventy bio's site for.

2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference

2seventy bio, Inc. (NASDAQ:TSVT ) Q2 2023 Earnings Conference Call August 14, 2023 8:00 AM ET Company Participants Jenn Snyder - SVP of Corporate Affairs Nick Leschly - President and Chief Executive Officer Philip Gregory - Chief Scientific Officer Steven Bernstein - Chief Medical Officer William Baird - Chief Financial Officer Conference Call Participants Daina Graybosch - Leerink Partners Yaron Werber - TD Cowen Kelsey Goodwin - Guggenheim Vikram Purohit - Morgan Stanley Daina Graybosch - Leerink Partners John Newman - Canaccord Genuity Operator Good day and thank you for standing by. Welcome to the 2seventy bio Second Quarter 2023 Earnings Conference Call.

2seventy bio, Inc. (TSVT) Q2 2023 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, will announce its second quarter 2023 financial results on Monday, August 14, 2023. 2seventy bio will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company's website at https://ir.2seventybio.com/.

2seventy bio to Report Second Quarter 2023 Financial Results on August 14, 2023

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immune-oncology cell therapy company, announced today that members of the management team will present at the upcoming 2023 Wedbush PacGrow Healthcare Conference on August 8, 2023 at 8:00am ET in New York. About 2seventy bio Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour –.

2seventy bio to Participate in 2023 Wedbush PacGrow Healthcare Conference

2seventy bio: Nothing Properly Explains The Low Valuation

Following a patient's death, investigators pause an early-stage study on 2seventy bio's (TSVT) CAR-T cell therapy in AML indication. However, it is still unclear whether the death was due to the treatment.

2seventy (TSVT) Down 9% on Patient Death in Leukemia Study

Seattle Children's Therapeutics paused a study of 2seventy Bio's AML treatment after a patient died. TSVT stock crumbled on the news.

2seventy Bio Stock Crumbles After A Patient Dies In Its Pediatric Cancer Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced that the Phase 1 trial of the PLAT-08 study of SC-DARIC33 in Acute Myeloid Leukemia (AML) has been paused by Seattle Children's, the Company's partner and the regulatory sponsor of the study. The pause was instituted as part of the clinical study protocol stopping rules in response to a recent Grade 5 (fatal) serious adverse event (SAE) and was followed by the re.

2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that members of the management team will participate in a fireside chat at the upcoming Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 6:20pm ET in Dana Point, CA. A live webcast will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. A replay will be archived on 2seven.

2seventy bio to Participate in Upcoming Investor Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced late-breaking results from the ongoing Phase 1 PLAT-08 trial, in collaboration with Seattle Children's Therapeutics, evaluating SC-DARIC33 in relapsed or refractory pediatric and young adult AML patients, as well as an oral presentation evaluating regulated IL-15 production combined with DARIC33 activation for anti-AML potency. The data were presented at this yea.

2seventy bio Presents Late-Breaking Results for SC-DARIC33, an Investigational CD33-Targeting CAR T in Pediatric and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced new data featuring novel approaches combining the company's platform CAR T cell and T cell receptor technology and unique cell therapy engineering capabilities to potentially enhance treatment potency in a range of cancers. The data were shared in three presentations at this year's American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Los Angeles,.

2seventy bio Presents Broad Range of New Data Highlighting Novel Approaches Across its Cell Therapies Portfolio

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) today announced the presentation of four abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 2-6, 2023 in Chicago, Illinois and six abstracts at the European Hematology Association (EHA) Congress, taking place in Frankfurt, Germany from June 8-11, 2023. The presentations will highlight clinical and correlative data from the KarMMa-2 and KarMMa-3 clinical trials evaluating Abecma.

2seventy bio Announces Additional Data from KarMMa Studies of Abecma (idecabtagene vicleucel) at ASCO 2023 and EHA 2023

2seventy bio, Inc. (NASDAQ:TSVT ) Q1 2023 Earnings Call Transcript May 3, 2023 4:30 PM ET Company Participants Jenn Snyder - SVP of Corporate Affairs Nick Leschly - President, CEO & Director Philip Gregory - Chief Scientific Officer Steven Bernstein - Chief Medical Officer William Baird - CFO Conference Call Participants Daina Graybosch - SVB Securities LLC Operator Good day, and thank you for standing by. Welcome to the 2seventy bio First Quarter 2023 Financial Results Conference Call.

2seventy bio, Inc. (TSVT) Q1 2023 Earnings Call Transcript

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today announced the presentation of five abstracts, including one late-breaking oral presentation, at this year's American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, California from May 16-20, 2023. The late-breaking abstract featuring early findings from the ongoing Phase 1 PLAT-08 trial in collaboration with Seattle Children's Thera.

2seventy bio to Present New Preclinical and Clinical Data from Broad Portfolio of Investigational Cell Therapies at the ASGCT 26th Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) a leading immuno-oncology cell therapy company, today announced that it has achieved a preclinical $15 million milestone as part of the joint research and development collaboration focused on an in vivo gene editing treatment for hemophilia A. The milestone is a result of delivering key pre-clinical proof of concept data that the Company plans to present during a virtual Research and Development deep dive on May 19, 2023. “Hem.

2seventy bio and Novo Nordisk Collaboration Delivers Key Proof of Concept Data, Triggering $15 Million Preclinical Milestone in In Vivo Gene Editing Hemophilia A Program

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will announce its first quarter 2023 financial results on Wednesday, May 3, 2023. 2seventy bio will host a conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Participants can access the conference call live via webcast which will be available on the investor page of the company's website at https://ir.2seventybio.com/. Participants.

2seventy bio to Report First Quarter 2023 Financial Results on May 3, 2023

Martinsried /M unich , March 29 , 2023 . Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today reported financial results for the year ended December 31, 2022 and provided a corporate update.

Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 60.78% and 236.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

2seventy bio, Inc. (TSVT) Reports Q4 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2022.

2seventy bio Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Progress

2seventy Bio's strong focus on cell therapy-based combinations for solid tumors positions them as a potential leader in the immuno-oncology market. Recent positive results from the KarMMa-3 study demonstrate the potential of the company's first-in-class anti-BCMA CAR T cell therapy, Abecma, to change the standard of care for multiple myeloma.

2seventy Bio: KarMMa-3 Finally Releases Positive Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) today announced the appointment of Wei Lin, M.D. to the company's Board of Directors, effective immediately. “We are thrilled to welcome Dr. Wei Lin to 2seventy's Board during an exciting time in our Company's growth,” said Nick Leschly, chief kairos officer.

2seventy bio Announces Appointment of Wei Lin, M.D. to Board of Directors

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that members of the management team will present at the 43rd Annual TD Cowen Health Care Conference at the Boston Marriott Copley Place in Boston, MA on March 7, 2023 at 10:30am ET. A live webcast will be available via the Investors and Media section of 2seventy bio's website at https://ir.2seventybio.com/. A replay will be archived on 2seventy bio's site for 30 days following the event.

2seventy bio to Participate in 43rd Annual TD Cowen Health Care Conference

CAMBRIDGE, Mass. , March 1, 2023 /PRNewswire/ -- Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announced the appointment of Kevin Chin, M.D.

Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (“2seventy bio”) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today the pricing of a follow on underwritten public offering of 10,869,566 shares of its common stock at a public offering price of $11.50 per share. All of the shares in the offering are being offered by 2seventy bio.

2seventy bio Announces Pricing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (“2seventy bio”) (Nasdaq: TSVT), a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer, announced today that it has commenced an underwritten public offering of $100 million of shares of its common stock. All of the shares in the proposed offering are being offered by 2seventy bio.

News for 2Seventy Bio Stock (TSVT)